Tuesday, February 28, 2017 1:17:29 PM
The Phase I Study of Encochleated Amikacin.
The Phase I study should meet the safety endpoint. The ongoing Phase I study of encochleated amikacin uses healthy subjects, and the only endpoint is safety. In that the Phase I studies of encochleated amphotericin B showed no toxicity, and only minor adverse events at the highest dosages, it would be a huge surprise if encochleated amikacin did not show similar safety in this ongoing Phase I trial.
I suspect that when the amikacin Phase I results are announced sometime this month, the share price will pop.
The Phase II Studies of Encochleated Amphotericin B.
However, the truly game changing clinical studies are the two ongoing trials for encochleated amphotericin B in which the endpoints are safety AND EFFICACY. If these results show that encochleated amphotericin B is as effective as non-encochleated amphotericin B, and has no toxicities, then we will truly have a disruptive technology, and a buy out will definitely be a possibility.
Topline results from the two Phase II studies are expected to be announced in 1H 2017.
The Phase III Pivotal Trial For the Prophylactic Use of Encochleated Amphotericin B.
From there, Matinas intends to ask the FDA for a pivotal Phase III registration trial for the prophylactic use of encochleated amphotericin B. If that trial were to be approved, that means the FDA will have found that this drug, which is so toxic it can only be administered in a hospital as a last resort, and for very short periods of time, is safe enough to be taken orally, at home, for a many months.
This would truly be game changing and disruptive especially if encochleation is shown to make many other highly toxic drugs safe and effective.
Conclusion
With so many catalysts on the near horizon, these are truly exciting times for Matinas. If Matinas' enclochleation technology can make effective but toxic drugs safe to administer, it is difficult to imagine this company not being the object of a big-pharma bidding war. If Matinas chooses to go it alone, the licensing fees from pharmaceutical companies seeking to use its patented encocleation technologies for a number of their effective but toxic drugs, together with Matinas' sale of its own encochleated drugs, should make Matinas a big player in the pharmaceutical industry.
LM
Recent MTNB News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:06:55 PM
- Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update • GlobeNewswire Inc. • 05/09/2024 08:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:01:52 PM
- Matinas BioPharma’s LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual Meeting • GlobeNewswire Inc. • 05/07/2024 12:00:00 PM
- Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024 • GlobeNewswire Inc. • 05/02/2024 11:00:00 AM
- In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy • GlobeNewswire Inc. • 04/30/2024 12:00:00 PM
- Matinas BioPharma Prices $10 Million Registered Direct Offering • GlobeNewswire Inc. • 04/03/2024 12:30:00 PM
- Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update • GlobeNewswire Inc. • 03/27/2024 08:05:00 PM
- Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response • GlobeNewswire Inc. • 03/22/2024 01:15:00 PM
- Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards • GlobeNewswire Inc. • 03/22/2024 10:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 01:05:14 PM
- Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution • GlobeNewswire Inc. • 02/26/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 12:35:32 PM
- Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis • GlobeNewswire Inc. • 02/20/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 12:30:25 PM
- Matinas BioPharma to Present at Biotech Showcase 2024 • GlobeNewswire Inc. • 01/03/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/27/2023 12:40:40 PM
- Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides • GlobeNewswire Inc. • 12/27/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 12:40:46 PM
- Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA • GlobeNewswire Inc. • 12/21/2023 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/16/2023 02:46:31 AM
FEATURED POET Announces Design Win and Collaboration with Foxconn Interconnect Technology for High-speed AI Systems • May 14, 2024 10:09 AM
FEATURED Element79 Gold Corp Reports Exceptionally High-Grade Results from Lucero • May 14, 2024 7:00 AM
VAYK Added New Manager for Expansion into $64 Billion Domestic Short-term Rental Market • VAYK • May 14, 2024 9:00 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM